Automated test generation for REST APIs: no time to rest yet
- Award ID(s):
- 2107125
- PAR ID:
- 10389431
- Date Published:
- Journal Name:
- Proceedings of the ACM SIGSOFT International Symposium on Software Testing and Analysis (ISSTA 2022)
- Page Range / eLocation ID:
- 289 to 301
- Format(s):
- Medium: X
- Sponsoring Org:
- National Science Foundation
More Like this
-
Introduction: RE1-silencing transcription factor (REST) silences neuronal differentiation genes. Its overexpression in an aggressive subset of gliomas is believed to support the enhanced tumor-initiating and self-renewal capacities of glioblastoma cancer stem cells (GSCs). Therefore, REST knockdown is hypothesized to inhibit tumor growth and recurrence. Because REST, as a large protein, is difficult to target directly with small molecules, our study focuses on knocking down REST by inhibiting one of its regulatory enzymes, small C-terminal domain phosphatase 1 (SCP1). Dephosphorylation of REST by SCP1 protects the former from degradation; consequently, SCP1 inhibition with an experimental drug, T62, is expected to reduce REST protein levels. This REST knockdown is hypothesized to induce the expression of neuronal differentiation genes, thereby forcing differentiation of GSCs and making them more vulnerable to standard treatments. We begin our study by validating patient-derived GSC lines and subsequently testing the efficacy of T62 drug in these cells. Our work supports an effort to understand various molecular pathologies of GBM and its intrinsic GSCs in order to develop novel therapeutic strategies.more » « less